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The resurgence of dengue (DEN) virus infections in the last few decades coupled with the lack of a preventive
vaccine and specific antiviral drugs has jointly contributed to making this a significant global public health
problem. Currently, symptomatic supportive treatment and fluid replacement therapy are the only means
available to minimize DEN-induced mortality. As the clinical symptoms associated with DEN virus infections
are indistinguishable from those of many other viral, bacterial, and parasitic infections, specific diagnostic
tests assume critical importance in the unequivocal identification of DEN virus infections. We have designed
a novel chimeric antigen based on envelope domain III (EDIII), a critical antigenic region of the major
structural protein of DEN viruses. We fused EDIIIs corresponding to each of the four DEN virus serotypes
using pentaglycyl linkers, overexpressed the resultant tetravalent chimeric protein in Escherichia coli, and
affinity purified it in high yields, obtaining 30 mg protein of >95% purity per liter of culture. We show that
this tetravalent antigen could specifically recognize anti-DEN virus antibodies of both the immunoglobulin M
(IgM) and IgG classes. Using a large panel of IgM antibody capture–enzyme-linked immunosorbent assay- and
hemagglutination inhibition-confirmed DEN virus-infected and uninfected patient sera (n  289), we demon-
strate that this tetravalent antigen can function as a diagnostic tool of high sensitivity and specificity.
Dengue (DEN) fever (DF), for which there is neither a vaccine
nor any therapeutic drug, is currently the most important arbo-
viral disease that places approximately half the global population
at risk (16, 35). While in the majority of cases, DF is clinically
inapparent, it can progress in some cases to a severe hemorrhagic
disease, dengue hemorrhagic fever (DHF), culminating in poten-
tially fatal dengue shock syndrome (DSS) (11, 14, 17, 35, 43). DF
and DHF/DSS are caused by infection with the mosquito-borne
DEN viruses, of which there exist four antigenically distinct sero-
types (DEN-1, -2, -3, and -4). These are members of the family
Flaviviridae, which includes other flaviviruses such as yellow fever
(YF), Japanese encephalitis (JE) and West Nile (WN) viruses
(32). It is estimated that annually there are about 50 to 100 million
cases of DF, of which 500,000 progress to DHF, leading to
25,000 deaths (12, 15–17). In untreated cases, mortality can be
as high as 40 to 50% (20, 35). This can be significantly minimized
by supportive care and symptomatic treatment through fluid re-
placement therapy (12). However, the combination of effective
patient care and management rests on early definitive diagnosis of
DEN virus infections. The clinical presentation of DF is often
indistinguishable from those of other infectious diseases such as
measles, influenza, typhoid, and other viral hemorrhagic fevers
(11). In recent years, models have been developed to distinguish
DF from other infections, based on clinical features and labora-
tory parameters such as white cell count, hemoglobin, prothrom-
bin time, and creatinine and bilirubin levels (7) and DHF based
on the use of an artificial neural network (19). However, these are
predictive models and cannot serve to substitute for actual diag-
nostic tests.
Definitive diagnosis of DEN virus infection depends on the
identification of infectious virus, its genomic RNA, virus-en-
coded antigens, or virus-induced antibodies (23, 39). Of these,
the first three are direct markers of DEN virus infection (that
depend on the presence of circulating virus) and can provide
highly sensitive and reliable indicators of current infection.
The traditional method of detection of infectious DEN virus in
patient sera either by mosquito inoculation or cell culture is
laborious, time-consuming, and not always successful. A recent
report has described an ultrasensitive method with the poten-
tial to detect single virions in serum. Using this technique, the
investigators demonstrated the detection of DEN virus
through its association with an anti-DEN virus antibody using
fluorescence cross-correlation spectroscopy (44). Viral RNA
can be detected with a high degree of sensitivity by coupled
reverse transcription-PCR (RT-PCR) but is subject to ampli-
con contamination and wide variability (30). To improve the
sensitivity of the RT-PCR assay further, Lien and coworkers
have devised an integrated microsystem in which the virus is
captured using antibodies conjugated to magnetic beads and
enriched in a magnetic field prior to RT-PCR (31). Both of
these technologies are nascent and have to be evaluated ex-
tensively. The complexity of such methods, the cost, and the
need for sophisticated equipment would preclude their routine
use, especially in a peripheral laboratory setting. Importantly,
the detection of DEN virus infections based on viral markers
that are dependent on the presence of circulating virus is of
limited practical utility as the infected individual is viremic only
for a short period of about 4 to 5 days (41). Often, DF patients
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do not seek immediate medical care because the initial
manifestations of infection may include mild fever or may be
asymptomatic. Thus, in a majority of cases the only feasible
diagnostic test would have to be based on the identification of
anti-DEN virus antibodies, which appear after the viremic
phase and persist much longer.
The qualitative nature of the antibody response depends
upon the immunological status of the individual at the time of
infection (21, 35, 39). While flavivirus-naı¨ve individuals mount
a primary antibody response, those experiencing a repeat in-
fection manifest a secondary antibody response. A primary
infection is characterized by the appearance of anti-DEN virus
immunoglobulin M (IgM) antibodies usually in 3 to 5 days
after onset of illness, peaking 2 weeks later and waning
thereafter. IgG antibodies which appear shortly afterwards
persist for several years. In contrast, in a secondary infection,
high-titer anti-DEN virus IgG antibodies appear either before
or along with IgM antibodies. Furthermore, IgM antibody ti-
ters tend to be significantly lower (21, 35, 39).
One of the earliest tests used to detect anti-DEN virus an-
tibodies was the hemagglutination inhibition (HI) test (42, 43).
The HI test, which measures the ability of serum antibody to
inhibit virus glycoprotein-mediated agglutination of erythro-
cytes (goose or human type O), is the World Health Organi-
zation (WHO) standard test for the serologic confirmation of
DEN virus infections. It utilizes whole-virus antigen prepared
from infected suckling mouse brain or insect cells in culture
and needs paired acute- and convalescent-phase sera. HI titers
displaying a 4-fold difference between the paired sera are
considered diagnostic of recent infection (42, 43). In contrast
to the HI assay, the IgM antibody capture–enzyme-linked im-
munosorbent assay (MAC-ELISA) can identify recent DEN
virus infections using a single serum specimen. In this assay,
anti-human IgM is used to capture anti-DEN virus IgM anti-
bodies, which in turn are revealed using a mixture of DEN
virus antigens in conjunction with an antiflavivirus antibody-
enzyme conjugate (14, 23, 42). Recently, several antibody de-
tection-based DEN diagnostic tests, in several different for-
mats, have become available commercially (10, 13, 42). Again,
the source of antigen is often infected mouse brain or insect
cell extracts. A major drawback stemming from the use of
whole-virus antigens, aside from the inherent biohazard risk, is
the inability of these tests to differentiate among the various
flaviviruses. This is due to the existence of shared antigenic
determinants among members of the family Flaviviridae (6).
Replacement of the whole-virus antigens with a mixture of
recombinant envelope (E) proteins of the four DEN virus
serotypes eliminated the safety risk but not the cross-reactivity
problem (10). In an attempt to eliminate this cross-reactivity,
we have focused on a discrete domain of the E protein, known
as domain III (EDIII).
In recent years, several studies have identified EDIII as a
critical immunodominant region of the DEN virus E protein.
EDIII, which spans amino acids (aa) 300 to 400 of the E
protein, is a highly stable, independently folding domain (4)
that lies exposed and accessible on the virion surface (27).
Multiple type- and subtype-specific neutralizing epitopes of the
E protein have been mapped to EDIII (9, 34, 37, 38). A variety
of studies have implicated this domain in host receptor binding
(4, 8, 9, 18). Using a mixture of TrpE-EDIII fusion proteins
corresponding to the four DEN virus serotypes, Simmons et al.
reported the successful detection of anti-DEN virus antibodies
of both IgM and IgG classes (40). Importantly, they also found
that sera from YF and JE virus IgG individuals who had not
been infected with DEN virus did not manifest any ELISA
reactivity towards the TrpE-DEN-EDIII mixture. Another
group, which used an immunoblot format, showed that recom-
binant EDIII (rEDIII) proteins could be used to serotype
DEN virus-infected patient sera (33). While this method did
not differentiate anti-DEN virus IgM or IgG class antibodies,
DEN virus-infected patient sera (all four serotypes) did not
react with JE and WN virus EDIIIs. Also, anti-WN virus EDIII
antiserum did not recognize any of the four DEN virus-specific
rEDIII proteins.
In this study, we created an rEDIII-T protein. We reasoned
that this rEDIII-T protein may not only retain the potential to
pick up anti-DEN virus antibodies (of both IgM and IgG
classes) specific to each of the four DEN virus serotypes but
would also obviate the need to express and purify four separate
proteins. We, therefore, decided to evaluate the diagnostic
utility of the rEDIII-T antigen in detecting anti-DEN virus
antibodies. Thus, in this report we describe the expression and
purification of the rEDIII-T antigen and an evaluation of its
potential as a diagnostic tool for the detection of anti-DEN
virus IgM and IgG antibodies using a large panel (n  289) of
well-characterized patient sera.
MATERIALS AND METHODS
Materials. Escherichia coli host strain DH5 was purchased from Invitrogen
(Carlsbad, CA). E. coli expression strain SG13009 (pREP4 [Kanr]), the expres-
sion plasmid pQE30 (Ampr), Ni-nitrilotriacetic acid (NTA) Super-flow resin, and
anti-His (penta-His) monoclonal antibody were from QIAGEN (Hilden, Ger-
many). Anti-mouse IgG–alkaline phosphatase (AP) conjugate and the substrate
5-bromo-4-chloro-3-indolyl phosphate–nitroblue tetrazolium (BCIP/NBT) were
from Calbiochem (EMD Chemicals, Inc., La Jolla, CA). Anti-human IgM- and
IgG–AP and anti-human IgM– and IgG–horseradish peroxidase (HRPO) con-
jugates were also from Calbiochem. The HRPO substrate, 3,3,5,5-tetramethyl-
benzidine (TMB), was from Kirkegaard Perry laboratories, Gaithersburg, MD.
The DEN MAC-ELISA (IgM capture ELISA) kit was from Focus Diagnostics,
Cypress, CA.
Human sera. We obtained serum specimens from febrile patients (n  201)
from areas of DEN endemicity in Sri Lanka after informed written consent. All
patients were warded at the North Colombo Teaching Hospital, Sri Lanka.
Ethical permission for the collection of blood samples was obtained from the
Ethical Committee, Faculty of Medicine, University of Kelaniya, Sri Lanka.
Acute-phase sera were drawn in the early symptomatic phase from each patient.
From several of them (n  88), convalescent-phase samples were obtained 1 to
2 weeks after the acute-phase sample. Thus, a total of 289 patient sera consisting
of 80 paired acute- and convalescent-phase DEN virus infection-confirmed sera,
82 single acute-phase and DEN virus infection-confirmed sera, 8 paired acute-
and convalescent-phase confirmed non-DEN patient sera, and 31 single acute-
phase confirmed non-DEN patient sera were available for this study. These sera
were stored immediately at 80°C for about a year before being used in this
study. Sera were tested for the presence of DEN virus, DEN virus RNA, and
anti-DEN virus IgM and IgG antibodies with established reference assays (29, 42,
43). A summary of the sera is presented in Table 1. More detailed information
is provided in the supplemental material.
In addition, a panel (n  6) of WHO reference sera containing four sera, each
with IgG antibodies specific to a single DEN virus serotype, a serum containing
IgG antibodies to all four DEN virus serotypes, and a flavivirus-naı¨ve serum were
obtained from Aravinda de Silva, North Carolina State University. Four patient
sera, confirmed to be JE virus seropositive by the method of Bundo and Igarashi
(5), were also included in the study.
Expression and purification of rEDIII-T antigen. A chimeric 1.5-kb
rEDIII-T gene, codon optimized for E. coli expression, was obtained by chemical
synthesis (GeneArt; Germany). This gene was designed to encode the EDIIIs
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(ranging from 115 to 119 aa residues) of all four DEN virus serotypes, with
adjacent EDIII units joined by pentaglycyl peptide linkers. The gene was ligated
into BamHI and HindIII restriction enzyme sites of the bacterial expression
vector pQE30, in frame with the vector-provided ATG codon and six-His tag-
encoding sequences, to generate the plasmid pQ-EDIII-T in E. coli DH5. For
expression, the plasmid was transformed into E. coli host strain SG13009 and
screened in test tube cultures. One clone that expressed the recombinant protein
maximally was sequence verified and used for recombinant protein purification.
All procedures were performed as previously described (2).
Purification was performed using 1 liter of isopropyl--D-1-thiogalactopyrano-
side (IPTG)-induced culture of an E. coli SG13009 clone harboring the pQ-
EDIII-T construct identified above. The entire purification was performed under
denaturing conditions throughout, essentially as described earlier (2). Briefly, the
cell pellet (2.5 g [wet weight]) was lysed by sonication in a denaturing buffer (6
M guanidine HCl, 100 mM sodium phosphate, 10 mM Tris-HCl, 300 mM NaCl
[pH 8]), clarified and chromatographed on an Ni-NTA matrix (bed volume, 4
ml). After washing, the bound proteins were eluted at acidic pH. Column frac-
tions were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE), and peak fractions were pooled, flash-frozen in liquid nitrogen,
and stored at 80°C until use.
Western blot analysis. To characterize the purified rEDIII-T protein, it was
subjected to SDS-PAGE, together with appropriate controls and prestained
protein markers, electroblotted onto nitrocellulose, and probed with penta-His
monoclonal antibody (MAb) and visualized using anti-mouse IgG–AP conjugate
and BCIP/NBT substrate as described previously (1, 2). To assess the reactivity
of rEDIII-T protein towards anti-DEN virus IgM and IgG antibodies, the puri-
fied protein was electrophoresed in a single wide well and blotted onto nitrocel-
lulose, which was then cut into narrow strips. Each strip was then probed sepa-
rately with DEN patient sera that were previously characterized to be IgM
IgG, IgM IgG, IgM IgG, and IgM IgG (1). We also used murine
anti-rEDIII-T antiserum and murine preimmune serum as positive and negative
controls, respectively. The secondary antibody-enzyme conjugate differed de-
pending on the probing serum used as the source of primary antibodies. For
strips that were probed with IgM IgG and IgM IgG patient sera, the
secondary antibody-enzyme conjugates used were anti-human IgM and anti-
human IgG, respectively. For strips probed with IgM IgG and IgM IgG
patient sera, either anti-human IgM– or IgG–enzyme conjugate was used. Fi-
nally, for strips probed with murine serum, we used anti-mouse IgG–enzyme
conjugate. All other procedural details were as reported earlier (1, 2).
In-house IgM and IgG ELISAs. Ninety-six-well flat-bottom ELISA plates
(Nunc, Roskilde, Denmark) were coated with 100 l of diluted rEDIII-T protein
(10 g/ml in 0.1 M carbonate buffer [pH 9.5]) and incubated at 37°C for 1 h. The
wells were blocked with 200 l of 5% skim milk in 1	 phosphate-buffered saline
at 37°C for 2 h and washed with 1	 phosphate-buffered saline–0.5% Tween
20–0.1% 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate five
times (1 min/wash). Washed wells were incubated with 100 l of patient serum
(diluted 1:100 in blocking buffer) at 37°C for 15 min. For IgG detection, wells
were washed again as described above and incubated with 100 l of anti-human
IgG–HRPO conjugate (diluted 1:10,000 in blocking buffer) at 37°C for 30 min.
Wells were washed again and incubated with 100 l of TMB soluble substrate at
37°C for 15 min. The reaction was stopped by adding 100 l of 1 M H2SO4. The
optical density value of each sample was measured at 450 nm with 630 nm as the
reference wavelength, using an ELx800UV microplate reader (Bio-Tek Instru-
ments, Inc., VT). For IgM detection, we used essentially the same protocol,
except that the secondary antibody-enzyme conjugate was anti-human IgM–
HRPO, for the following reasons. We have found a 15-min incubation step to be
adequate for serum IgM determinations (1). Furthermore, prior removal of
serum IgG using Pansorbin cells (catalog no. 507861; Calbiochem) did not result
in any significant improvement in IgM ELISA titers.
Sera were designated as either positive or negative for the presence of anti-
DEN virus IgM and IgG antibodies using cutoff absorbance values of 0.54 and
0.34, respectively. These cutoff values were obtained from the mean ELISA
absorbance of 47 confirmed non-DEN serum samples plus 3 standard deviations
(SD). DEN virus infection was ruled out in these patients based on RT-PCR,
virus isolation, HI assay, and a commercial MAC-ELISA kit (Focus Diagnostics).
Pooled DEN virus-seropositive and -seronegative samples, identified in our
earlier studies (1, 2), were included in each run to control for interassay varia-
tion.
Statistical analysis. The SD of the mean was calculated using the SPSS 15.0
package. A chi-square test (Epi 6, version 6.04d, software; Centers for Disease
Control and Prevention) was used for comparison of data obtained using
rEDIII-T antigen-based in-house IgM and IgG ELISAs (test methods) with the
corresponding reference methods, MAC-ELISA and HI assays, respectively.
Two variables were analyzed at a 95% confidence interval, and P values of 
0.05
were considered significant.
RESULTS
Design of the EDIII-T antigen. We chose EDIII as a pre-
cursor to create a tetravalent antigen, rEDIII-T, that would be
potentially able to recognize antibodies specific to each of the
four DEN virus serotypes. This chimeric antigen was designed
to contain the EDIIIs of the four DEN virus serotypes, inter-
linked by pentaglycyl linkers. This antigen is predicted to have
a molecular size of 55 kDa. A synthetic gene (EDIII-T gene)
encoding this tetravalent antigen, codon optimized for expres-
sion in E. coli, was inserted in-frame with the initiator codon
and a six-histidine tag-encoding sequence of the bacterial ex-
pression vector pQE30. The map of the resultant plasmid,
pQ-EDIII-T, is shown in Fig. 1A. This plasmid was trans-
formed into E. coli host strain SG13009 containing the pREP4
plasmid, which encodes the lacI repressor (required for regu-
lated recombinant gene expression) and the kanamycin
marker. The resultant double recombinants were analyzed by
expression screening, wherein IPTG-induced cells were di-
rectly lysed in Laemmli sample buffer and analyzed by SDS-
PAGE. Figure 1B depicts the induction profile of a typical
clone. Induction of the EDIII-T gene resulted in the appear-
ance of a new 55-kDa band (compare lanes I and U), con-
sistent with the predicted size of the rEDIII-T protein. When
induced cells were lysed by sonication in a native buffer, sep-
arated into supernatant and pellet fractions as described be-
fore (22), and analyzed by SDS-PAGE, the protein was found
to be predominantly present in the insoluble fraction (data not
shown).
TABLE 1. Summary of patient sera used in this studya
Panel (n)b Diagnosisc
No. of samples
Virus
infectedd
Serology All
negativegIgMe HIf
1 (80)h Confirmed DEN 30 42 43 8
2 (82) Confirmed DEN 18 60 54 0
3 (39)h Confirmed non-DEN 0 0 0 39
a Both acute-phase (early symptomatic phase) as well as convalescent-phase (1
to 2 weeks later) samples were collected; the data shown are for the acute-phase
sera. (For details, see the supplemental material.)
b Eighty patients for whom paired acute- and convalescent-phase sera could be
collected were placed in panel 1. Eighty-two DEN virus infection-confirmed
patients for whom single acute-phase sera were available were assigned to panel
2. Panel 3 consisted of 39 acute-phase febrile patients confirmed to be non-DEN
cases. Of these, paired sera were available from 8 patients, while single acute-
phase samples were collected from the remaining 31.
c Based on the presence of DEN virus RNA and/or a positive IgM and/or HI
test in conjunction with clinical presentation.
d DEN virus RNA in sera was detected by RT-PCR; infectious virus could be
isolated successfully from several RT-PCR-positive sera.
e Anti-DEN virus IgM antibodies were detected using a commercial MAC-
ELISA kit (Focus Diagnostics).
f Laboratory confirmation of DEN infection was defined by positive detection
of a 4-fold rise in anti-DEN virus IgG antibody titers in paired sera; HI titers
of 
20 were identified as non-DEN cases.
g Sera that tested negative by RT-PCR, virus isolation, MAC-ELISA, and HI
assay.
h Convalescent-phase sera were obtained (1 to 2 weeks after collection of
acute-phase sera) from all 80 patients in panel 1 and from 8 patients in panel 3.
All panel 1 convalescent-phase sera were IgM HI, while all 8 convalescent-
phase panel 3 sera were IgM HI.
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Purification and characterization of the rEDIII-T antigen.
The rEDIII-T protein was purified by a single-step Ni-NTA
affinity chromatography utilizing the six-His tag engineered at
its N terminus. As the majority of the rEDIII-T protein was
insoluble, the affinity chromatography was carried out under
denaturing conditions throughout. An SDS-PAGE analysis of
different fractions obtained during purification is presented in
Fig. 2A. Under the experimental conditions, almost all of the
recombinant protein bound to the column, as evident from a
comparison of the polypeptide profiles of the initial lysate
(lane L) and the flowthrough material (lane F). Elution of the
bound proteins after extensive washing resulted in the emer-
gence of highly purified protein (lanes E1 to E7). We estimate
the purity to be at least 95% on the basis of comparison of
the protein profiles of the eluted material (peak in lane E4)
and the crude lysate (lane L). We obtained a yield of 30 mg
rEDIII-T protein, corresponding to 95% recovery, starting
from 1 liter of induced E. coli culture.
We tested the purified protein in a Western blot assay. An
aliquot of pooled purified protein was probed with a commer-
cially available murine penta-His MAb specific to the engi-
neered six-His tag of the recombinant protein. It is evident
from the data shown in Fig. 2B that the penta-His MAb spe-
cifically recognized the Ni-NTA-purified 55-kDa rEDIII-T
protein.
The rEDIII-T antigen recognizes IgM and IgG antibodies in
DEN patient sera. Using the purified rEDIII-T antigen, we
next sought to evaluate its ability to specifically recognize hu-
man anti-DEN virus antibodies of both IgM and IgG classes.
To this end, we performed a Western analysis in which the
rEDIII-T protein, transferred onto nitrocellulose strips, was
probed separately with several different antisera known to ei-
ther contain or lack anti-DEN virus antibodies. We used sera
that were characterized in our earlier studies (1, 2). In this
experiment, the binding of anti-DEN virus IgM and anti-DEN
virus IgG antbodies in the sera to rEDIII-T was identified
using anti-human IgM and anti-human IgG secondary anti-
body conjugates, respectively. The results of this immunoblot
analysis are presented in Fig. 2C. As positive controls, we
included the penta-His MAb as in the previous experiment
(lane 6), as well as a murine anti-rEDIII-T polyclonal serum
(lane 5). As expected, both of these specifically recognized the
rEDIII-T protein. Preimmune murine serum, which served as
the negative control, did not pick up the recombinant protein
(lane 7). When the strips were probed with an IgM IgG
DEN patient serum, the rEDIII-T could be visualized if the
secondary antibody was anti-human IgM (lane 1) but not anti-
human IgG (lane 4). Similarly, when the primary serum used
for probing was IgM IgG, the tetravalent protein was dis-
cernible in the blot if the secondary antibody was anti-human
IgG (lane 3) but not anti-human IgM (lane 2). The rEDIII-T
protein could also be detected in the strip blots when probed
with a double-positive (IgM IgG) but not double-negative
(IgM IgG) serum, irrespective of the secondary antibody-
enzyme conjugate used (data not shown). Taken together,
these data strongly indicate that the rEDIII-T protein can
specifically recognize and bind to both anti-DEN virus IgM
and anti-DEN virus IgG antibodies in patient sera.
The rEDIII-T protein recognizes antibodies specific to mul-
tiple DEN serotypes. The question that we sought to address at
this point was whether the rEDIII-T protein would recognize
human antibodies specific to each one of the four DEN virus
serotypes. To address this question, we obtained a WHO ref-
erence serum panel (n  6) with samples containing IgG an-
tibodies to single DEN virus serotypes, IgG antibodies to all
FIG. 2. Purification and immunoblot analysis of the rEDIII-T pro-
tein. (A) SDS-PAGE analysis of Ni-NTA affinity column fractions
obtained during the purification of rEDIII-T protein. The samples
analyzed in the gel are load (lane L), flowthrough (lane F), and eluates
(lanes E1 to E7). Protein molecular mass markers were run in lane M;
their sizes in kDa are shown to the left. The arrow to the right indicates
the position of the rEDIII-T protein. (B) Western blot analysis of the
purified rEDIII-T protein using the penta-His MAb. An aliquot of the
purified recombinant protein was run in lane R. A protein without His
tag (bovine serum albumin) was run in lane B as a negative control.
Prestained protein molecular mass markers were run in lane P; their
sizes in kDa are shown to the left. The arrow to the right indicates the
position of the rEDIII-T protein. (C) Western blot analysis performed
with nitrocellulose strips onto which purified rEDIII-T protein had
been transferred after SDS-PAGE. The test strips were probed with
IgM IgG (lanes 1 and 4) or IgM IgG (lanes 2 and 3) confirmed
DEN patient sera. The penta-His MAb (lane 6), murine anti-rEDIII-T
polyclonal serum (lane 5), and murine preimmune serum (lane 7) were
used to probe the control strips. The rEDIII-T protein was visualized
using anti-human IgM (lanes 1 and 2)–, anti-human IgG (lanes 3 and
4)–, or anti-murine IgG (lanes 5 to 7)–enzyme conjugate. Prestained
molecular mass markers were run in lane P; their sizes in kDa are
indicated to the left. The arrow to the right indicates the position of the
rEDIII-T antigen.
FIG. 1. Expression of r-EDIII-T protein in E. coli. (A) Map of the
expression plasmid. The synthetic rEDIII-T gene was inserted into the
BamHI and HindIII sites of plasmid pQE30, in-frame with the vector-
provided ATG and six-His tag-encoding sequence. Abbreviations are
as follows: pT5/lac O, prokaryotic promoter under lac operator con-
trol; rEDIII-T, synthetic gene encoding the tetravalent antigen; t1 and
t2, transcriptional terminators; Ori and AmpR, plasmid replication
origin and ampicillin resistance marker, respectively. (B) Coomassie-
stained denaturing gel showing the polypeptide profiles of E. coli
harboring the plasmid in panel A before (lane U [uninduced]) and
after (lane I [induced]) IPTG induction. Protein molecular mass mark-
ers were run in lane M; their sizes in kDa are shown to the left. The
arrow to the right indicates the position of the rEDIII-T protein.
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four DEN virus serotypes, and a sample lacking flaviviral an-
tibodies. These reference sera were tested in an in-house
ELISA using rEDIII-T antigen to capture the anti-DEN virus
IgG antibodies, followed by detection of the bound antibodies
using the anti-human IgG–HRPO conjugate. The results sum-
marized in Table 2 lead to the conclusion that indeed the
rEDIII-T protein manifests a high level of reactivity towards
anti-DEN virus IgG antibodies of all four DEN virus serotypes.
The unavailability of the corresponding anti-DEN virus IgM
antibody-containing reference panel precluded the possibility
of addressing the question of whether the rEDIII-T antigen
would bind IgM antibodies specific to each of the four DEN
virus serotypes. However, we found during the collection and
characterization of patient sera for evaluation of the rEDIII-T
protein (below) several samples that tested positive for DEN
virus genomic RNA by RT-PCR (Table 1). Of these we could
identify two DEN-2 virus-positive and 16 DEN-3 virus-positive
sera, all of which manifested significant levels of reactivity in an
rEDIII-T antigen-based in-house IgM ELISA, as shown in
Table 3. While this assay was similar to the in-house IgG
ELISA described above, in that we again utilized rEDIII-T
protein as the coating antigen, it differed in one important
respect, namely, the use of anti-human IgM in the detection
phase, instead of anti-human IgG. Unfortunately, we could not
identify DEN-1 and DEN-4 viruses in any of the DEN virus-
confirmed sera used in this study. In regard to anti-DEN virus
IgM antibody recognition, available data demonstrate specific-
ity for DEN virus serotypes 2 and 3. Patient sera that were
positive for JE virus-specific antibodies failed to manifest any
significant reactivity towards the DEN virus-derived rEDIII-T
protein. Mean (SD) absorbance values of these JE virus
sera (n  4) in the in-house IgM and IgG ELISA were 0.17
(0.08) and 0.31 ( 0.12), respectively.
Detection of anti-DEN virus IgM and IgG antibodies in
patient sera. Based on these encouraging observations, we next
proceeded to evaluate the utility of this tetravalent antigen as
a diagnostic tool for the detection of both anti-DEN virus IgM
and IgG antibodies using a large collection of confirmed DEN
and non-DEN patient sera (Table 1). All of these sera (n 
289) were screened using the rEDIII-T antigen-based in-house
IgM and IgG ELISAs described above (see the supplemental
material). In parallel, each sample was also tested using the
MAC-ELISA and HI assay as reference assays for anti-DEN
virus IgM and IgG antibodies, respectively. The results of the
in-house IgM ELISA are depicted in Fig. 3. With regard to
acute-phase sera from DEN-confirmed patients, about half of
panel 1 sera (Fig. 3A) and nearly three-quarters of panel 2 sera
(Fig. 3B) were found to be IgM based on their reactivity
towards the rEDIII-T protein in the in-house IgM ELISA.
Interestingly, 100% of the panel 1 convalescent-phase sera
were found to be IgM (Fig. 3A). The panel 3 acute-phase
samples which tested negative using the MAC-ELISA failed to
display any significant reactivity towards the rEDIII-T protein
in the in-house IgM ELISA. This was true for the panel 3
convalescent-phase sera as well (Fig. 3C). It is to be pointed
out that all panel 3 sera also tested negative in the virus cul-
ture, RT-PCR, and HI assays (Table 1). A comparison of the
in-house IgM ELISA data with those of the reference MAC-
ELISA is shown in Table 4. We found that 55% of the con-
firmed DEN patient sera tested positive for the presence of
anti-DEN virus IgM antibodies with the in-house IgM ELISA.
Significantly, each of these sera also tested positive with the
reference MAC-ELISA. Likewise, 29% of the confirmed DEN
patient sera which tested negative in the in-house IgM ELISA
also tested negative in the reference MAC-ELISA.
Next, we examined the capacity of the rEDIII-T antigen to
detect anti-DEN virus IgG antibodies as well using the in-
house IgG ELISA. For this experiment, we used the HI assay
as the reference, which is the WHO “gold standard” assay for
confirming DEN virus infections (43). The in-house IgG
ELISA data for all 289 sera are presented in Fig. 4. With
regard to acute-phase sera, the data showed that about half of
panel 1 (Fig. 4A) and two-thirds of panel 2 (Fig. 4B) sera were
IgG. However, all panel 1 convalescent-phase sera were in-
variably IgG (Fig. 4A). Once again all of the panel 3 sera
TABLE 2. Reactivity of WHO reference sera in the in-house
IgG ELISA
Sample Virus serotype
Anti-DEN
virus IgG
status
In-house IgG
ELISA A450
Ref-1 DEN-1 Positive 5.00
Ref-2 DEN-2 Positive 1.76
Ref-3 DEN-3 Positive 1.92
Ref-4 DEN-4 Positive 1.70
Ref-5 All 4 DEN virus
serotypes
Positive 2.63
Ref-6 Flavivirus naı¨ve Negative 0.40
TABLE 3. Reactivity of viremic sera in the in-house IgM ELISA
Panel Virus serotypea No. of serumsamples
In-house ELISA
mean A450
(range)b
1 DEN-3 7 2.45 (1.47–5.00)
2 DEN-2 2 1.07 (0.92–1.22)
DEN-3 9 2.27 (0.83–5.00)
a Virus serotype was identified by RT-PCR (29). Infectious virus could be
isolated from both DEN-2 virus- and 12 DEN-3 virus-infected sera.
b The values in this column indicate the reactivity of anti-DEN virus IgM
antibodies to rEDIII-T protein in terms of mean A450; the values in parentheses
indicate the range of observed absorbance values.
FIG. 3. Analysis of anti-DEN virus IgM antibodies in patient sera
using rEDIII-T antigen-based in-house IgM ELISA. Anti-DEN virus
IgM antibodies in serum panels 1 (A), 2 (B), and 3 (C) were tested in
an ELISA using the rEDIII-T protein as the capture antigen. Bound
IgM antibodies were detected using anti-human IgM–HRPO conju-
gate in conjunction with TMB substrate. The dotted line indicates the
cutoff absorbance (A450 of 0.54). Acute- and convalescent-phase sera
are indicated by the solid and open symbols, respectively.
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(both acute as well as convalescent phase), which tested neg-
ative in the reference assay (HI titers of
20), did not manifest
any significant IgG ELISA reactivity (Fig. 4C). A comparison
of the in-house IgG ELISA results with those of the HI assay
is presented in Table 4. About 54% of the DEN virus-con-
firmed sera which manifested the presence of rEDIII-T anti-
gen-reactive IgG antibodies were also HI, with titers of
2,560 for the majority of these samples. Furthermore, 35%
of these DEN virus-confirmed sera, which did not have any
rEDIII-T antigen-reactive IgGs, also tested negative in the HI
assay.
Discrepant sera. It is evident that the results of the in-house
IgM and IgG ELISAs agreed with those of the cognate refer-
ence assays in most but not all samples tested. With regard to
anti-DEN virus IgM status, the in-house ELISA results of 84%
of the DEN virus-confirmed sera agreed with those obtained
using the reference MAC-ELISA (Table 4). Thirteen sera
which were identified as IgM based on the reference MAC-
ELISA were found to be IgM based on the in-house ELISA.
Similarly, another set of 13 sera were IgM in the MAC-
ELISA but IgM in the in-house ELISA. The in-house IgM
ELISA data for the discrepant sera, which did not conform to
the MAC-ELISA results, are presented in Fig. 5A. About 25%
of the discrepant sera were borderline cases, with the rest
resulting in absorbance values that fell clearly below or above
the cutoff mark in the in-house IgM ELISA. Interestingly, such
inconsistencies were not evident when the anti-DEN virus IgM
status of convalescent-phase sera was tested by these two as-
says. A total of 88 convalescent-phase sera (80 from panel 1
and 8 from panel 3) gave identical results in both the test and
reference assays for anti-DEN virus IgM antibodies. While all of
the panel 1 convalescent-phase sera (n  80) tested positive, all
panel 3 convalescent-phase sera (n  8) tested negative for anti-
DEN virus IgM antibodies in both the MAC-ELISA as well as the
in-house IgM ELISA (see the supplemental material).
Again as with the in-house IgM ELISA, we found that a
small percentage of the sera analyzed by the in-house IgG
ELISA yielded discrepant results with reference to the HI
assay data, as shown in Fig. 5B. Ten HI sera, with titers
ranging from 80 to 2,560, tested negative in the in-house IgG
ELISA. Similarly, nine sera that were IgG in the in-house
ELISA were HI (HI titers of 
20). Once again, the discrep-
ancies between the test and reference assays were indiscernible
for the convalescent-phase sera (see supplemental material).
All panel 1 convalescent-phase sera (n  80), which were
designated as IgG, were also HI. Of these, 10 were primary
infections (with HI titers ranging from 80 to 640) and the rest
were secondary infections (HI titers of 2,560). Likewise, all
panel 3 convalescent-phase sera (n  8), which were IgG,
displayed HI titers of 
20. Interestingly, the discrepant IgM
and IgG serum groups were largely distinct from each other,
with just two sera being common to both groups (see the
supplemental material).
Performance evaluation of the diagnostic utility of the
rEDIII-T antigen. A summary of an analysis performed by
comparing the rEDIII-T antigen-based in-house IgM and IgG
TABLE 4. Evaluation of rEDIII-T protein as a DEN diagnostic antigen
Antibody
statusa
No. of samples tested to determine the presence ofb:
Anti-DEN virus IgM Anti-DEN virus IgG
Panel 1 Panel 2 Panel 3 Total Panel 1 Panel 2 Panel 3 Total
Ref Test 37 52 0 89 38 49 0 87
Ref Test 7 6 0 13 2 7 0 9
Ref Test 5 8 0 13 5 5 0 10
Ref Test 31 16 39 86 35 21 39 95
a Ref, antibody present as determined by the reference assay; Ref, antibody absent as determined by the reference assay; Test, antibody present as determined
by the in-house ELISA; Test, antibody absent as determined by the in-house ELISA. Anti-DEN virus IgM antibodies were determined using the commercial
MAC-ELISA kit (Ref) and the in-house IgM ELISA (Test). Anti-DEN IgG antibodies were determined using the HI assay (Ref) and the in-house IgG ELISA (Test).
The cutoff values (mean  3 SD) used for the IgG and IgM in-house ELISAs were 0.34 and 0.54, respectively.
b A total of 201 samples were tested. The number of samples in each panel was as follows: in panel 1, 80 samples; in panel 2, 82 samples; and in panel 3, 39 samples.
FIG. 4. Analysis of anti-DEN virus IgG antibodies in patient sera using rEDIII-T antigen-based in-house IgG ELISA. Anti-DEN virus IgG
antibodies in serum panels 1 (A), 2 (B), and 3 (C) were tested in an ELISA using the rEDIII-T protein as the capture antigen. Bound IgG
antibodies were detected using anti-human IgG–HRPO/TMB. The dotted line indicates the cutoff absorbance (A450 of 0.34). Acute- and
convalescent-phase sera are indicated by the solid and open symbols, respectively.
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ELISA data with data generated using the reference assays is
presented in Table 5. An overall comparison of the data for the
acute-phase sera in terms of sensitivity, specificity, and concor-
dance suggests that there is excellent agreement between our
in-house ELISAs and the currently accepted MAC-ELISA and
HI reference assays (43). Interestingly, the use of the rEDIII-T
antigen-based in-house ELISAs for the detection of anti-DEN
IgM and IgG antibodies in convalescent-phase sera (n  88)
showed complete agreement of all three parameters with re-
spect to the cognate reference assays. Statistical analysis re-
vealed no significant difference between the results generated
using the in-house IgM-ELISA and reference MAC-ELISA
(2  187; P  0.0); similarly, there was no significant differ-
ence between the in-house IgG-ELISA and the reference HI
assay (2  214; P  0.0).
DISCUSSION
As DEN virus infections are endemic to resource-poor na-
tions and generally coprevalent with other flaviviral infections,
an ideal DEN diagnostic test designed to detect DEN virus-
induced antibodies would have to satisfactorily meet four es-
sential criteria, namely, safety, high sensitivity, high specificity,
and low cost. This work is based on the premise that such a
diagnostic test would have to be based on an antigen which
should (i) be a recombinant protein; (ii) incorporate immuno-
dominant antigenic features unique to each one of the DEN
virus serotypes, as multiple serotypes often cocirculate in many
areas of endemicity; (iii) specifically recognize anti-DEN virus
antibodies of both IgM and IgG classes, while at the same time
avoiding cross-reactivity towards other flavivirus-induced anti-
bodies; and (iv) be amenable to inexpensive production. We
recently developed a novel multiepitope strategy to create an-
tigens with customized specificity. Using this strategy, we de-
signed two first generation multiepitope proteins, one specific
for IgM (1) and the other specific for the IgG (2) class (2) of
anti-DEN antibodies. In this work, we have developed a sec-
ond generation antigen, rEDIII-T, with the potential to detect
both anti-DEN virus IgM and IgG antibodies. This antigen was
created by linking together the EDIIIs corresponding to the
four DEN virus serotypes. Our choice of the EDIII as the
precursor in creating this tetravalent molecule was dictated by
several key properties, such as its emergence as a critical and
unique antigenic region (4, 8, 9, 18, 24–26, 34, 37, 38, 40), its
ability to recognize anti-DEN virus antibodies of both IgM and
IgG classes (40), and its lack of significant cross-reactivity to-
wards antibodies induced by heterologous flaviviruses (3, 33,
40).
To express the rEDIII-T antigen, we designed a gene en-
coding the EDIIIs of each of the four DEN virus serotypes
linked by pentaglycyl linkers. It has been shown that in design-
ing chimeric proteins, glycine is one of the preferred linker
residues capable of conferring flexibility owing to its lack of a
-carbon (36). A 5 six-His tag-encoding sequence was engi-
neered into this gene, which was then overexpressed in E. coli
using an IPTG-inducible promoter. A major proportion of the
rEDIII-T antigen remained in the insoluble phase, as is often
the case with several proteins overexpressed in E. coli. This
necessitated its purification on Ni-NTA matrix under denatur-
ing conditions. Analysis by SDS-PAGE revealed that this one-
step affinity chromatography had resulted in95% purity, with
a yield of 30 mg/liter of E. coli culture. Consistent with its
ability to bind the Ni-NTA matrix, the purified protein could
be detected with the penta-His MAb in a Western blot. Im-
portantly, it also manifested immunoreactivity towards both
anti-DEN virus IgM and anti-DEN virus IgG in Western blot
analysis. This observation is consistent with the report of Sim-
mons et al. (40), led to the conclusion that the rEDIII-T anti-
gen does indeed possess both IgM and IgG antibody-specific
epitopes and suggested that this antigen has the potential to
detect anti-DEN virus antibodies of both IgM and IgG classes
in patient sera. Furthermore, our observation that JE virus
sera did not manifest discernible reactivity to the rEDIII-T
protein in the in-house ELISAs corroborated earlier reports
that flavivirus antibodies do not cross-react with heterologous
rEDIII proteins (3, 33, 40).
To ascertain if indeed the rEDIII-T antigen would recognize
FIG. 5. ELISA reactivities of the discrepant sera. (A) ELISA re-
activities of patient sera that manifested inconsistent results in the
in-house IgM ELISA (Test) with reference to the commercial MAC-
ELISA (Ref). (B) ELISA reactivities of patient sera that manifested
inconsistent results in the in-house IgG ELISA (Test) with reference
to the HI assay (Ref). The in-house IgM and IgG ELISA cutoffs,
indicated by the dotted lines, were 0.54 and 0.34, respectively. Ref
Test and Ref Test sera are indicated by open and solid symbols,
respectively.
TABLE 5. Performance parameters assessed by comparison of the EDIII-T-based IgM and IgG ELISA results with those of the
corresponding reference methods
Sera (n)
IgM IgG
% Sensitivitya % Specificityb % Concordancec % Sensitivitya % Specificityb % Concordancec
Acute phase (201) 86 (89/104) 89 (86/97) 87 (175/201) 90 (87/97) 91 (95/104) 91 (182/201)
Convalescent phase (88) 100 (80/80) 100 (8/8) 100 (88/88) 100 (80/80) 100 (8/8) 100 (88/88)
a Values in parentheses are numbers of sera antibody-positive by both tests/numbers of sera positive by only the reference assay.
b Values in parentheses are numbers of sera antibody-negative by both tests/numbers of sera negative by only the reference assay.
c Values in parentheses are numbers of sera with concordant reference and in-house test results/total number of sera.
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anti-DEN virus antibodies specific to each of the four DEN
virus serotypes, we performed an ELISA experiment using a
WHO reference serum panel. In this experiment, we tested the
ability of the rEDIII-T antigen to interact separately with anti-
DEN virus IgG antibodies specific to each DEN virus serotype.
This experiment demonstrated clearly that anti-DEN virus IgG
antibodies of each one of the four serotypes were indeed rec-
ognized efficiently by the rEDIII-T antigen. The lack of a
corresponding reference panel (of serotype-specific anti-DEN
virus IgM-containing sera) precluded experimental testing of
the ability of the rEDIII-T antigen to recognize anti-DEN virus
IgM antibodies of each of the four DEN virus serotypes as
well. However, it seems reasonable to assume that rEDIII-T
most likely possesses this ability. We base this on our obser-
vation that in our panel of 201 acute-phase patient sera, we did
identify DEN-2 and DEN-3 virus-infected sera, which were
IgM by the reference MAC-ELISA as well as our in-house
IgM ELISA.
Next, we proceeded to evaluate the utility of the rEDIII-T
protein as a DEN diagnostic antigen. A large panel of acute-
and convalescent-phase sera (n  289) from confirmed DEN
and non-DEN patients was tested for anti-DEN virus antibod-
ies using two well-established assays, the HI assay and the
MAC-ELISA (43). The acute-phase sera were also tested for
the presence of virus by mosquito cell culture and for viral
RNA by RT-PCR (29). The performance of the rEDIII-T
protein as a diagnostic antigen for the detection of anti-DEN
virus antibodies was evaluated using these characterized sera.
To this end, we designed in-house ELISAs using the rEDIII-T
as the coating antigen to capture serum anti-DEN virus anti-
bodies. Captured IgM and IgG antibodies were detected using
anti-human IgM–HRPO and anti-human IgG–HRPO conju-
gates, respectively. The resultant data were compared to the
data from the MAC-ELISA and HI assay. Of these two assays
that served as our reference assays, the former is specific for
anti-DEN virus IgM antibodies, whereas the latter measures
both IgM and IgG classes of antibodies (42). Nevertheless, we
have used the HI assay results as a reference for our in-house
IgG ELISA results. This is because most of the sera were
obtained from cases of secondary infection, in which it is well
recognized that the anamnestic IgG response that occurs
within a few days of infection (acute phase) results in high HI
titers (2,560) in the convalescent phase. Furthermore, it has
been demonstrated that anti-DEN virus IgG titers show a good
correlation with HI titers (28).
We used panel 3 sera to define the cutoff absorbance values
for our in-house ELISAs. Each serum in this panel was shown
to be negative for the presence of DEN virus and anti-DEN
virus antibodies by multiple criteria (Table 1). Furthermore,
none of the 39 febrile patients from whom the panel 3 sera
were collected clinically progressed to DF/DHF. Finally, con-
valescent-phase sera collected from these patients 2 weeks
later were still seronegative for anti-DEN virus antibodies in
the MAC-ELISA as well as HI assay. Clearly, this group con-
stitutes confirmed non-DEN cases.
Out of the 162 DEN virus-confirmed sera, 136 tested iden-
tically in both the reference MAC-ELISA and the in-house
IgM ELISA, with both assays scoring 89 sera as IgM and the
rest as IgM (n  47). However, 26 of the DEN virus-con-
firmed sera gave discrepant results in the in-house IgM ELISA.
The in-house IgM ELISA did not identify 13 sera that scored
positive in the reference MAC-ELISA. This raises questions
regarding the sensitivity of the rEDIII-T protein-based IgM
ELISA. However, a closer examination of the ELISA data
revealed that many of these sera represent borderline samples
(Fig. 5A). It is likely that these discrepant sera, which presum-
ably lack detectable levels of EDIII-specific anti-DEN virus
IgM antibodies, apparently contain MAC-ELISA-reactive E
antigen-specific anti-DEN virus IgM antibodies directed at
epitopes outside domain III. Intriguingly, the remaining 13
discrepant sera, which were MAC-ELISA negative, turned out
to be positive in the in-house IgM ELISA. But for a couple of
borderline cases, the rest manifested significantly high ELISA
reactivities (absorbance at 450 nm ranging from 1.47 to 5; n 
11) in the in-house IgM ELISA. It is unlikely that these are
false positives. That the observed data for these samples do
indeed reflect genuine DEN virus infection is apparent from
the fact that a majority of these sera (9 of 11 samples) con-
tained DEN virus RNA (see the supplemental material). Ad-
ditionally, seven of these yielded infectious virus in mosquito
cell culture. This indicated that these nine sera were indeed
positive for anti-DEN virus IgM antibodies, leading to the
suggestion that the reference MAC-ELISA kit had missed
scoring these sera as IgM. In contrast, convalescent-phase
sera corresponding to these nine acute-phase samples scored
positive in the MAC-ELISA (as well as by the in-house IgM
ELISA). Clearly, the rEDIII-T antigen-based in-house IgM
ELISA is superior to the commercial MAC-ELISA kit in de-
tecting early seroconversion.
With regard to the utility of the rEDIII-T antigen in the
detection of anti-DEN virus IgG antibodies, 87 of 162 DEN
virus-confirmed sera displayed rEDIII-T antigen-specific anti-
DEN virus IgG antibodies. This was corroborated for all of
these sera by data from the HI assay (HI titers were predom-
inantly 2,560). Fifty-six sera did not manifest the presence of
anti-DEN virus IgG antibodies in the in-house assay, a result
that was mirrored by insignificant HI titers (
20) for all of
these 56 sera. As seen in the in-house IgM ELISA, we once
again found a small number (n  19) of sera that generated
discrepant results in the in-house IgG ELISA with reference to
the HI assay data. Ten discrepant sera, which were HI, tested
negative in the in-house IgG assay. These are borderline cases
based on their low ELISA absorbance values (Fig. 5B). In
contrast, eight of the remaining nine discrepant sera, which
were HI, displayed significant reactivity in the in-house IgG
ELISA (with A450 values ranging from 0.75 to 5). One of these
acute-phase sera, the only one out of this group for which a
convalescent-phase serum was available, manifested the high-
est observed reactivity (Fig. 5B) in the in-house IgG ELISA
but did not contain any anti-DEN virus IgM antibody as de-
termined by both the reference and test assays. The corre-
sponding convalescent-phase serum, however, manifested HI
titers of 2,560, and this patient was designated as having a
case of secondary DEN virus infection. Another sample from
this group of nine discrepant sera, which was also IgM, was
also viremic. This is also presumably a case of secondary DEN
virus infection. With regard to these two sera, it is likely that
the presence of high anti-DEN virus IgG antibodies in the
acute phase, as evidenced by significant in-house IgG ELISA
reactivity, coupled to the lack of any discernible anti-DEN
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virus IgM antibodies (by both reference and in-house assays)
perhaps represents the anamnestic IgG response, which had
presumably preceded and overshadowed the IgM response.
Interestingly, six of these nine sera were also IgM by both
MAC-ELISA and the in-house IgM assay. The simultaneous
detection of anti-DEN virus IgM and anti-DEN virus IgG
antibodies in the acute phase indicates that all these sera rep-
resent secondary infections.
An overall assessment of the in-house ELISA data in rela-
tion to the reference assays shows that the rEDIII-T antigen
possesses the potential for dual detection of both anti-DEN
virus IgM and IgG antibodies in patient sera. While the sen-
sitivity, specificity, and concordance were 86%, 89%, and 87%,
respectively, for IgM detection, the corresponding values were
90%, 91%, and 91%, respectively, for IgG detection in acute-
phase sera. Importantly, the rEDIII-T-based IgM antibody
detection was more sensitive in identifying early seroconver-
sion than the reference assay. In the convalescent phase, the
performance of both of the in-house ELISAs was indistin-
guishable from that of the reference assays in terms of sensi-
tivity, specificity, and concordance. Based on our data, efforts
are under way to develop a rapid strip test for the simultaneous
detection of both anti-DEN virus IgM and IgG antibodies. In
conclusion, we believe that our approach of fusing all four
EDIIIs to create a tetravalent recombinant antigen coupled to
high-level expression and single-step purification has the po-
tential to lead to the development of an ideal DEN diagnostic
test suitable for use, particularly, in the resource-poor regions
of DEN endemicity around the globe.
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